Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

The European Commission (EC) has approved Biocon Biologics’ biosimilars referencing Amgen’s bone disease therapy denosumab.

The stock’s current performance reflects a positive investor response, with Biocon demonstrating promising financial results ...

Bangalore: Biocon has announced the appointment of Ekta Agarwal as the Interim Company Secretary and Compliance Officer ...

Bhosale's top pick is Prestige Estates Projects with a stoploss of Rs 1,600. "The stock is looking very positive on the daily ...

Syngene International Ltd., an integrated research, development, and manufacturing services organization, in partnership with ...

Clinical studies have demonstrated that both biosimilars are comparable in safety and efficacy to the reference product, the ...

Expert CA Rudramurthy BV suggests a bullish stance. He recommends buying on dips, especially in pharma stocks like Glenmark, ...

Biocon Biologics receives marketing authorizations for Vevzuo and Evfraxy biosimilars for bone-related diseases in the UK.

For most people, the fear isn’t dying—it’s the slow decline that precedes it. The emerging philosophy aims to delay that ...

Biocon Biologics receives UK MHRA approval for Vevzuo & Evfraxy, biosimilars of Denosumab, to treat bone diseases in adults & ...

Biocon Biologics Ltd received UK approval for Vevzuo and Evfraxy, biosimilars of Denosumab. Vevzuo is approved for ...